Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK). The collaboration aims to leverage Tempus’ proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics’ oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus’ de-identified multimodal database to support the biotech’s clinical trial designs by focusing on the right patient population with the highest level of demonstrated real-world unmet need. The collaboration will center on powering research spanning Whitehawk Therapeutics’ ADC portfolio, which includes three assets designed to target clinically validated proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI selected by ARPA-H to provide CRO services
- tempus AI Inc Class A call volume above normal and directionally bullish
- Tempus AI Stock (TEM) Spikes 9%— Should You Buy Now?
- Ambry Genetics announces improved EHR-integrated BC risk assessment solution
- Short Report: Tempus AI short interest reaches record high